Several preclinical studies have reported potential therapeutic tools for the treatment of human cancers, that target the translation machinery, such as mTOR inhibitors (e.g., Rapamycin, Torin 1), eIF4E inhibitors (e.g., 4EGI-1, 4E1RCat), and MNK inhibitors (e.g., Cercosporamide, CGP57380) [20]. This evidence concerns the gene EIF4E and cancer.